What Researchers Did
Researchers studied how hyperbaric oxygen therapy (HBOT) affects the body's processing of the drug lidocaine in two healthy volunteers.
What They Found
The study found that hyperbaric oxygen therapy (HBOT) at 2.5 ATA did not significantly change how the body processed lidocaine, with pharmacokinetic parameters remaining similar to previous findings. However, under HBOT conditions, volunteers experienced more severe side effects like marked dizziness, buzzing in the ears, sweating, tremor, and coordination problems, even though lidocaine levels (0.63-0.70 mg/L) were well below therapeutic levels (1.5-5.0 mg/L).
What This Means for Canadian Patients
For Canadian patients who might receive lidocaine while undergoing hyperbaric oxygen therapy (HBOT), this study suggests that HBOT itself does not alter how their body processes the drug. However, patients may experience more pronounced side effects from lidocaine, such as dizziness or tremor, during HBOT sessions, even at doses typically considered safe. Healthcare providers should monitor patients closely for these symptoms if lidocaine is administered during HBOT.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
A significant limitation of this study is its very small sample size of only two volunteers, which limits the generalizability of the findings.